Literature DB >> 11046154

The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes.

J M Petersen1, L S Her, V Varvel, E Lund, J E Dahlberg.   

Abstract

The matrix (M) protein of vesicular stomatitis virus (VSV) is a potent inhibitor of bidirectional nuclear transport. Here we demonstrate that inhibition occurs when M protein is in the nucleus of Xenopus laevis oocytes and that M activity is readily reversed by a monoclonal antibody (alphaM). We identify a region of M protein, amino acids 51 to 59, that is required both for inhibition of transport and for efficient recognition by alphaM. When expressed in transfected HeLa cells, M protein colocalizes with nuclear pore complexes (NPCs) at the nuclear rim. Moreover, mutation of a single amino acid, methionine 51, eliminates both transport inhibition and targeting to NPCs. We propose that M protein inhibits bidirectional transport by interacting with a component of the NPC or an NPC-associated factor that participates in nucleocytoplasmic transport.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11046154      PMCID: PMC102164          DOI: 10.1128/MCB.20.22.8590-8601.2000

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  59 in total

Review 1.  Getting across the nuclear pore complex.

Authors:  B Talcott; M S Moore
Journal:  Trends Cell Biol       Date:  1999-08       Impact factor: 20.808

2.  Analysis of VSV mutant with attenuated cytopathogenicity: mutation in viral function, P, for inhibition of protein synthesis.

Authors:  C P Stanners; A M Francoeur; T Lam
Journal:  Cell       Date:  1977-06       Impact factor: 41.582

3.  A novel receptor-mediated nuclear protein import pathway.

Authors:  V W Pollard; W M Michael; S Nakielny; M C Siomi; F Wang; G Dreyfuss
Journal:  Cell       Date:  1996-09-20       Impact factor: 41.582

4.  Identification and characterization of a nuclear pore complex protein.

Authors:  L I Davis; G Blobel
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

5.  The use of Xenopus oocytes for the expression of cloned genes.

Authors:  J B Gurdon; M P Wickens
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

6.  Rapid inhibition of processing and assembly of small nuclear ribonucleoproteins after infection with vesicular stomatitis virus.

Authors:  L D Fresco; M G Kurilla; J D Keene
Journal:  Mol Cell Biol       Date:  1987-03       Impact factor: 4.272

7.  The C-terminal domain of TAP interacts with the nuclear pore complex and promotes export of specific CTE-bearing RNA substrates.

Authors:  A Bachi; I C Braun; J P Rodrigues; N Panté; K Ribbeck; C von Kobbe; U Kutay; M Wilm; D Görlich; M Carmo-Fonseca; E Izaurralde
Journal:  RNA       Date:  2000-01       Impact factor: 4.942

8.  Vesicular stomatitis virus M protein in the nuclei of infected cells.

Authors:  D S Lyles; L Puddington; B J McCreedy
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Heat shock disassembles the nucleolus and inhibits nuclear protein import and poly(A)+ RNA export.

Authors:  Y Liu; S Liang; A M Tartakoff
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

10.  Virus replication in enucleate cells: vesicular stomatitis virus and influenza virus.

Authors:  E A Follett; C R Pringle; W H Wunner; J J Skehel
Journal:  J Virol       Date:  1974-02       Impact factor: 5.103

View more
  87 in total

1.  Matrix protein and another viral component contribute to induction of apoptosis in cells infected with vesicular stomatitis virus.

Authors:  S A Kopecky; M C Willingham; D S Lyles
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

2.  Multiple vesiculoviral matrix proteins inhibit both nuclear export and import.

Authors:  J M Petersen; L S Her; J E Dahlberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-10       Impact factor: 11.205

3.  Inhibition of nuclear import and alteration of nuclear pore complex composition by rhinovirus.

Authors:  Kurt E Gustin; Peter Sarnow
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

4.  Intranuclear degradation of nonsense codon-containing mRNA.

Authors:  Marc Bühler; Miles F Wilkinson; Oliver Mühlemann
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

5.  Novel nuclear herniations induced by nuclear localization of a viral protein.

Authors:  Cristen C Hoyt; Ron J Bouchard; Kenneth L Tyler
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

6.  Introgression of Drosophila simulans nuclear pore protein 160 in Drosophila melanogaster alone does not cause inviability but does cause female sterility.

Authors:  Kyoichi Sawamura; Kazunori Maehara; Shotaro Mashino; Tatsuo Kagesawa; Miyuki Kajiwara; Kenji Matsuno; Aya Takahashi; Toshiyuki Takano-Shimizu
Journal:  Genetics       Date:  2010-07-20       Impact factor: 4.562

7.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

8.  Vesicular stomatitis virus infection alters the eIF4F translation initiation complex and causes dephosphorylation of the eIF4E binding protein 4E-BP1.

Authors:  John H Connor; Douglas S Lyles
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

10.  Bidirectional increase in permeability of nuclear envelope upon poliovirus infection and accompanying alterations of nuclear pores.

Authors:  George A Belov; Peter V Lidsky; Olga V Mikitas; Denise Egger; Konstantin A Lukyanov; Kurt Bienz; Vadim I Agol
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.